I 129V

Drug Profile

I 129V

Alternative Names: I129V

Latest Information Update: 18 Mar 2008

Price : $50

At a glance

  • Originator Genencor International
  • Class Recombinant proteins
  • Mechanism of Action Interferon beta stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Multiple sclerosis

Most Recent Events

  • 13 Jun 2005 Genencor International has been acquired by Danisco A/S
  • 26 Jan 2004 Preclinical trials in Multiple sclerosis in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top